AstraZeneca/$AZN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Ticker

$AZN
Sector
Primary listing

Employees

94,300

AstraZeneca Metrics

BasicAdvanced
$263B
15.92
$5.31
0.15
$1.54
1.20%

What the Analysts think about AstraZeneca

Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.

Bulls say / Bears say

AstraZeneca’s experimental hypertension drug baxdrostat met its primary endpoint in a late-stage trial for treatment-resistant hypertension, paving the way for a regulatory filing by end-2025 and targeting over $5 billion in peak annual sales (Reuters)
The $555 million licensing agreement with Algen Biotechnologies secures exclusive rights to AI-driven CRISPR gene-editing platforms, bolstering AstraZeneca’s cell and gene therapy pipeline and supporting its $80 billion revenue goal by 2030 (Reuters)
AstraZeneca topped second-quarter profit expectations with an 11% revenue increase to $14.46 billion and core EPS of $2.17—surpassing forecasts thanks to strong oncology and U.S. sales—reinforcing its growth trajectory (Reuters)
AstraZeneca delayed trial results for its lung-cancer candidate AVANZAR until 2026, deferring anticipated revenue contributions and slowing its oncology pipeline rollout (Reuters)
A UK court invalidated AstraZeneca’s Forxiga patent in April and upheld that decision on appeal in July 2025, exposing its SGLT2 franchise (approximately 15% of product revenue) to immediate generic competition in the UK (SEC filing)
Alexion, an AstraZeneca subsidiary, faces a U.S. class-action lawsuit alleging anticompetitive patent manipulations on its blockbuster drug Soliris, with over $2 billion in claimed damages that could materialize if the suit succeeds (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

AstraZeneca Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AstraZeneca Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AZN

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs